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Abstract
The guidelines for the curative treatment of prostate can-
cer presented by the German Society of Urology are dis-
cussed. They are based on the current knowledge of the
outcomes of surgical and radiotherapeutic treatment for
prostate cancer. Radical prostatectomy is recommended
as the first-line treatment for organ-confined prostate
cancer in patients with an individual life expectancy of at
least 10 years. Radiotherapy can be considered as an
alternative treatment modality, although current knowl-
edge does not allow a definite assessment of the relative
value of radiotherapy compared to radical prostatecto-
my. Locally advanced cT3 prostate cancer is overstaged
in about 20% and curative treatment is possible in select-
ed cases. Guidelines represent rules based on the avail-
able evidence. This implies that exceptions must be
made whenever appropriate and that guidelines have to
be reviewed regularly as new information becomes
available.
Copyright © 1999 S. Karger AG, Basel
Zusammenfassung
Die Leitlinien der Deutschen Gesellschaft für Urologie
zur kurativen Therapie des Prostatakarzinoms werden
diskutiert. Sie beruhen auf dem gegenwärtigen Wissens-
stand über die Ergebnisse der operativen und strahlen-
therapeutischen Behandlung. Demnach wird die radikale
Prostatektomie als primäre Standardtherapie für alle Pa-
tienten mit organbegrenztem Tumor, die eine indivi-
duelle Lebenserwartung von mindestens 10 Jahren ha-
ben, empfohlen. Die Strahlentherapie kann dabei als
Alternative gelten, jedoch ist bislang eine klare Beurtei-
lung der relativen Wertigkeit der Strahlentherapie im
Vergleich zur operativen Therapie noch nicht möglich.
Lokal fortgeschrittene Tumoren (cT3) sind bei 20% pT2
(overstaging), so dass eine Kuration in selektionierten
Fällen möglich ist. Leitlinien sind Regeln, die aufgrund
des verfügbaren Wissensstandes erstellt werden. Dies
beinhaltet, dass erforderliche Ausnahmen gemacht
werden können und dass Leitlinien immer wieder über-
arbeitet werden müssen, wenn neue Erkenntnisse dies
erfordern.
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Introduction
Prostate cancer has received increased attention in the
developed industrial nations during the last two decades
for several reasons. It has a high incidence among popula-
tions with a long life expectancy and it therefore has an
important impact on the quality of life of a population
that can expect to live 7 or 8 decades. With a high preva-
lence of latent prostate cancer in the elderly, the lifetime
cumulative risk of overt prostate cancer is about 10% up
to the age of 75 in the United States [1].
Advances in the early diagnosis of prostate cancer have
been due to the detection of a reliable serum marker, the
prostate-specific antigen (PSA), in 1979 [2] and the use of
ultrasound-guided systematic prostate biopsies. The
widespread use of PSA for the detection of prostate cancer
has led not only to an increase in its incidence but also to a
shift towards the diagnosis of more organ-confined stages
of the disease. More recently, the diagnosis of prostate
cancer has further been improved by the differentiation
between total and free PSA [3].
At the same time, progress in urologic surgery and in
perioperative intensive care management has advanced the
frontiers of urological operative management principles,
and transformed radical prostatatectomy from a highly
specialized to a routine procedure in experienced hands.
Simultaneously, radiotherapy has also made considerable
advances in its management possibilities of prostate cancer
by refinements of dosimetry with modern imaging tech-
niques, megavolt X-rays and effective radioactive isotopes.
Improved results are reported for modern, conformal per-
cutaneous radiotherapy. A new interest in interstitial radio-
therapy has been kindled by the advent of palladium in the
form of commercially available seeds.
Competing Treatment Modalities
The increased incidence and the widespread availabili-
ty of specialized treatment modalities has focussed the
discussion on who to treat and how to treat. It is impera-
tive that the results of controlled multicenter trials or
from metaanalyses of many large trials are used to pro-
vide the evidence that is needed to answer these ques-
tions. Due to a relative paucity of mature trials so far, and
the long disease course of prostate cancer, several ques-
tions which are under discussion cannot be answered with
certainty at this stage.
One of these important questions concerns the relative
roles of radiotherapy and surgery in the treatment of
organ-confined prostate cancer, another circumstance
under which ‘watchful waiting’ can be considered a rea-
sonable strategy. While watchful waiting remains an op-
tion in patients with life expectancies of less than 10 years,
an international consensus seems to emerge that prostate
cancer should be actively treated in patients young
enough to live another decade.
The relative roles of radiotherapy versus radical pros-
tatectomy are under continuing intensive discussion.
However, at present it cannot be decided with absolute
certainty which of the two treatment modalities, if any, is
better in long-term patient survival, since randomized
prospective long-term outcome trials that would permit a
clear conclusion in this respect are not available so far.
However, the metaanalysis of Adolfsson [4] clearly indi-
cates an advantage for radical prostatectomy.
The outcome of surgery and radiotherapy in the treat-
ment of prostate cancer can be assessed at the clinical, the
pathological and the biochemical levels. Clinical assess-
ment is based on patient survival, evidence of local recur-
rence by DRE and on the diagnosis of metastases by stan-
dard evaluation. Pathological results refer to the evidence
of cancer tissue in post-treatment biopsies and are impor-
tant in the follow-up of radiotherapeutic modalities. Bio-
chemical treatment results refer to post-treatment PSA
measurements and their significance in assessing treat-
ment success or failure.
After radical prostatectomy, the clinical results are
excellent in that long-term survival at 10 and 15 years has
been reported to be 92–97 and 86–94%, respectively [5].
At the same time, 15–27% of patients with organ-con-
fined tumors will develop local recurrence and, of these,
16% will die of prostate cancer within a 10-year period
and up to 70% later [5, 6]. Similarly, in a multi-center
analysis of 2,758 men with T1 and T2 prostate cancer
after radical prostatectomy, 10-year survival rates of 94,
80 and 77% were reported for grade 1–3 tumors, respec-
tively [7]. Clearly, with small organ-confined cancers
tumor differentiation is the most important prognostic
factor after radical prostatectomy.
The aim of radical prostatectomy is the complete
removal of the localised prostate cancer. Problems of clin-
ical staging lead to a certain degree of failure in achieving
this goal. Systematic pathological evaluation of radical
prostatectomy specimens allows tumor classification into
the three surgical categories of organ confined (intracap-
sular), specimen-confined (extracapsular with negative
surgical margins) and those with positive surgical mar-
gins. Only organ-confined prostate cancers with a low
Gleason score can reliably be cured by radical prostatecto-
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my [8].Organ-confined prostate cancers used to range
between 37 and 50% in older radical prostatectomy series
[9, 10]. More recently, due to the stage shift with a higher
proportion of T1c patients and improved surgical tech-
nique, the rate of positive margins has decreased [8]. The
frequency of extracapsular disease is related to tumor
stage: 68% in T2b, 33% in T2a disease and still 26% in
T1b, thus depending on tumor volume [10]. Penetration
of the prostatic capsule carries an unfavorable prognosis
with a progression rate of 46% within 10 years [11]. With
organ-confined tumors, the risk of postoperative progres-
sion of the disease depends on preoperative PSA, tumor
DNA ploidy and pathological grade [12].
Ideally, after complete radical prostatectomy for or-
gan-confined disease, PSA should be undetectable in the
serum. Persistence and a rise in post-surgery PSA above
0.1 ng/ml is considered evidence of disease. The long-
term failure rate at 10 years after radical prostatectomy is
related to the incidence of early postoperative PSA detec-
tion in the serum, and amounts to 12% for organ-con-
fined, 30% for specimen-confined and 60% for positive-
margin cases [13]. In a more recent analysis, the risk of
progression with margin-positive disease has been calcu-
lated to be 27% within 5 and 46% within 10 years after
radical prostatectomy [8].
When post-surgery PSA persistence is considered a cri-
terion of not declaring ‘no evidence of disease’ (NED) sta-
tus after radical prostatectomy, in some series only 40% of
pT2 will have NED 10 years after radical prostatectomy
as compared to 90% based on survival without clinical
evidence of disease [14]. Similarly, for pT2A and pT2B
disease, PSA-inclusive NED at 10 years of 76 and 52%
has been reported [15]. The preoperative PSA level seems
of predictive importance since at 10 years after radical
prostatectomy, 90% of patients with a preoperative PSA
!4 ng/ml will have an undetectable PSA, while with a pre-
operative PSA of 10–20 ng/ml only 56% of patients will
achieve this goal [15]. Thus, major predictive factors for
the success of radical prostatectomy for localized prostate
cancer are tumor stage, Gleason score and initial PSA.
There is no doubt that radiotherapy is an efficient
treatment and does achieve cure in localized prostate can-
cer. External beam radiotherapy with a dose of 60–70 Gy
is delivered to the true pelvis and the prostate itself. No
benefit could be demonstrated for extended field irradia-
tion including pelvic lymph nodes. Clinically, external
beam radiotherapy has been reported to achieve 10-year
survival rates for T1/2 prostate cancer of 65–86%, and of
62% at 15 years [5], however, in patients treated by surgi-
cal pelvic lymphadenectomy with negative lymph nodes.
Local failure occurs in up to 20% of cases [16–18], meta-
static disease in up to 30% [5].
Pathological results of radiotherapy can be assessed by
posttreatment biopsies of the prostate. The rate of posi-
tive biopsies after radiation treatment varies widely be-
tween 18 and 90%, depending on the selection of patients
for biopsy, the technique used and the time after radiation
treatment [19, 20]. However, 70% of patients with cT1 or
cT2 disease treated by radiotherapy can have a negative
biopsy at 2 years. While clinical survival can be much lon-
ger, local failure and metastatic disease have been re-
ported to occur in 45–66% and 60–80% of cases with pos-
itive biopsies [19–21].
PSA is reduced significantly after radiation treatment.
There is no consensus regarding the PSA nadir following
radiation treatment which can be considered the mark of
successful cure. While it is usually set at !1 ng/ml, some
set it as low as !0.5 ng/ml.
While radiotherapy has few immediate complications
and side effects and seems therefore less invasive to the
patient, it does have a definite long-term morbidity. Com-
plications are dose- and field-related and improved tech-
niques will in future undoubtedly improve posttreatment
morbidity. Severe and moderate complications occur in 3
and 7%, respectively. Patients who have undergone trans-
urethral resection are at risk of developing incontinence
or strictures. Radiation cystitis and proctitis occur in 5–
6% each. Impotence is a problem in 15–40% of patients.
It is important to realize that the posttreamtent problems
of radiation often tend to increase with time.
The renewed interest in brachytherapy as a treatment
modality for prostate cancer is based on the development
of radioactive seeds with short half-lives such as palla-
dium and transrectal or perineal implantation techniques
with modern imaging techniques. Interstitital radiothera-
py of prostate cancer itself was used at the beginning of
this century and later as the surgical implantation of gold
seeds [22]. Often, brachytherapy is combined with exter-
nal beam radiotherapy and treatment results are thus dif-
ficult to compare. With modern image-based posttreat-
ment dosimetry, it has become apparent that the distribu-
tion of the radiation dose applied with seed implantation
varies widely [23]. The complications are similar to those
of external radiotherapy, if somewhat less pronounced. As
with external beam radiotherapy, treatment results are
difficult to assess and the discussion depends on the inter-
pretation of posttreatment biopsies and PSA. PSA-pro-
gression-free survival is greater in patients treated by radi-
cal prostatectomy in comparison to patients treated by
brachytherapy [24, 25]. However, treatment figures for
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brachytherapy are low and larger trials will be needed
before this treatment modality can be definitely assessed.
While Paulson’s study on the relative outcomes of radi-
cal prostatectomy and radiotherapy published in 1982
[26] already showed an advantage for the treatment by
radical prostatectomy, this study has been severely criti-
cised for methodological reasons. However, a more recent
metaanalysis showed an advantage for radical prostatec-
tomy as well [27]. Radiotherapy trials often suffer from a
selection bias in that patients with locally more advanced
disease and patients with other severe medical problems
who are not candidates for radical prostatectomy are
referred for radiotherapy and are included in outcome
trials. While postprostatectomy results can easily be de-
fined in their curative success by PSA measurement, the
problem of assessing curation after radiotherapy is diffi-
cult and always comes back to progression-free survival.
The value of radical prostatectomy is clearly defined as a
curative treatment for organ-confined disease, that of
radiotherapy much less. This dilemma cannot be solved
at present. Thus, it will be some more years before the
ongoing dispute about the relative roles of radiotherapy
and radical surgery in prostate oncology will be settled.
Selecting Treatment Options
Organ-confined prostate cancer is potentially curable
by complete surgical removal of the whole prostate gland
together with the seminal vesicles. While this is technical-
ly possible, the results of the procedure depend on wheth-
er cure has been achieved and on the long-term morbidity
of the operation in terms of incontinence and impotence.
The major drawback of the surgical approach to pros-
tate cancer is that preoperative staging has definite limita-
tions in its accuracy and that clinical staging will not reli-
ably differentiate between T2 and T3 disease. It is also not
possible to confidently exclude lymph node metastases in
every case.
Radiotherapy can achieve cure and its results are bet-
ter for small prostate cancers as well. The prediction of
treatment results is more difficult and complications in
the individual are unpredictable in the long run.
With these limitations in mind, guidelines for the man-
agement of prostate cancer will have to focus on the fol-
lowing points. Which patients and what tumor stages are
successfully and best treated surgically? Which surgical
procedures should be employed? When should radiother-
apy be recommended?
Patient Selection for Radical Prostatectomy
General Considerations
General considerations underlying the selection of pa-
tients for radical prostatectomy as the first line of treat-
ment are those of life expectancy based on empirical con-
siderations and individual factors in view of biological
versus chronological age and comorbidity. It is accepted
that radical prostatectomy should only be considered for
individuals whose remaining life expectancy is or exceeds
10 years.
The general life expectancy of a 72-year-old man in the
United States in 1991 was just over 10 years [28]. Similar
life expectancies apply to Western Europe. However,
there are many individuals whose general health and
family history of longevity suggests a longer life expectan-
cy so that the decision to operate should be based on the
individual state of health and personal situation. Signifi-
cant comorbidity, especially cardio- and cerebrovascular
disease, must be taken into account as it has a clear
impact on survival in men aged 65–75 years [29].
Specific Considerations
The single most important specific consideration
which is important for patient selection for radical prosta-
tectomy is tumor stage. Other prognostic factors which
are known to have a definite impact on postoperative
long-term survival such as Gleason score and PSA must
also be included in the decision-making process.
Preoperative tumor staging based on PSA, transrectal
ultrasonography and nuclear bone scanning will result in a
stage assessment that includes a definite margin of error.
While nuclear bone scans are not required if PSA is
!10 ng/ml [30], there is no definite value in using CT or
MRI imaging at all since the sensitivity and specificity in
detecting lymph node metastases is low. Understaging of
clinical T1/T2 disease occurs in 30–40% of cases [31, 32].
This staging error will have an impact for individual
patients as well as for the overall results of radical prosta-
tectomy.
Nevertheless, the decision to operate will by necessity
be based on clinical staging. Preoperative prognostic fac-
tors are clinical stage, Gleason score and PSA [8, 33, 34].
The main indication for radical prostatectomy is clini-
cally organ-confined disease (T1 and T2). There is no
definite consensus about the value of radical surgery in T3
disease and its role in patients with lymph node involve-
ment is disputed. Patients with metastatic disease defi-
nitely are not candidates for radical prostatectomy.
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Organ-Confined Disease
T1aN0
Patients with an incidental carcinoma of the prostate
found in less than 5% of the tissue resected at transure-
thral resection generally have a reasonably good prognosis
and can therefore be offered different treatment options.
A significant difference in long-term survival between
watchful waiting and radical prostatectomy in these pa-
tients does not become apparent before 10 and 15 years
[35, 36]. Patients with a life expectancy of 10 years or
more should be offered radical prostatectomy; external
beam radiotherapy is an alternative. Patients who do not
meet these criteria can be followed with watchful wait-
ing.
T1bN0
These patients with an incidentally discovered prostat-
ic carcinoma of more than 5% of the tissue resected have a
considerable tumor volume. Watchful waiting in these
patients carries a much less favourable prognosis than in
stage T1a patients. These patients should therefore all be
offered curative treatment. They are definitely candidates
for radical prostatectomy if they meet the general critera
of life-expectancy and comorbidity. Again, percutaneous
radiation is an alternative.
T1cN0
Patients with an elevated PSA and a nonpalpable
tumor diagnosed by random biopsies form a large and
increasing group of men diagnosed with prostate cancer
today. This increase in the PSA-based detection of clini-
cally inapparent tumors accounts for the stage shift in
diagnosis that has been observed. T1c patients are often
relatively young patients with long life expectancy. At the
same time these patients are those who are most con-
cerned about postprostatectomy impotence. While pres-
ervation of potency is a major issue in this group of
patients, they are most definitely candidates for radical
prostatectomy, and should be offered a nerve-sparing pro-
cedure. While principally radiotherapy is an alternative in
these patients as well, a successful nerve-sparing radical
prostatectomy offers a high chance of cure with no long-
term liabilities in terms of later complications.
T2N0
Patients with clinically palpable and organ-confined
disease can be treated by radical prostatectomy, bearing
in mind the problems of clinical understaging. Disease in
both lobes of the prostate (T2b) carries a less favorable
prognosis. However, complete removal of the prostate in
organ-confined disease offers the best chance of cure. 10-
year survival rates after radical prostatectomy in this
group of patients ranges between 85 and 90% [37–40].
PSA-based progression-free rates at 5 years range between
69 and 85% [41].
Again, radiotherapy is an alternative. While the dis-
puted study of Paulson et al. [26] suggested better survival
rates for T2 patients treated by radical prostatectomy in
comparison to those treated by radiotherapy, this issue is
at present undecided [42].
Locally Advanced Disease
T3N0
The value of radical prostatectomy for this group of
patients is doubtful since the risk of micrometastases is
considerable, and many patients will have positive lymph
nodes. The chance of curative treatment is therefore low
in the majority of patients with T3 disease.
Radical prostatectomy improves local control and thus
quality of life in T3 patients, and for this reason patients
in this group may be considered for radical prostatectomy
on an individual bases. Following radical prostatectomy,
it seems prudent to treat these patients adjuvantly with
hormonal deprivation [43]. However, results from several
clinical studies suggest that cancer-specific survival may
be increased. Reported clinical progression-free survival
rates at 5 and 10 years of patients with T3N1/2 disease
treated by radical prostatectomy with pelvic lymphaden-
ectomy and androgen deprivation were 41–83 and 25–
71%, respectively [44–49].
Similarly, radiotherapy as a localized treatment will
not be curative for the majority of these patients. Local
control may possibly be improved by adjuvant radiother-
apy after radical prostatectomy for pT3 disease [50].
Techniques and Problems of Radical
Prostatectomy
The standard technique of radical prostatectomy is the
retropubic approach, either with an ascending or descend-
ing technique. Alternatively, radical perineal prostatecto-
my is favored by some urologists and laparoscopic retro-
pubic radical prostatectomy today is also becoming an
alternative.
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Radical Retropubic Prostatectomy
This technique is the worldwide standard approach. It
has the advantage of allowing a pelvic lymphadenectomy
at the same time and providing good exposure. Periopera-
tive mortality today ranges between 0 and 1.5% in large
series [51, 52]. Anastomotic insufficiency occurs in 1.2–
4% of cases [53, 54].
Incontinence remains a controversial issue in that the
assessment is not standardized. While rates of severe post-
operative incontinence will generally be low, the rates of
minor incontinence will vary widely depending on the
definition of continence used, and whether data are
assessed by urologists or taken from patient surveys.
Long-term postoperative incontinence persisting after ap-
propriate physiotherapy after 1 year has been reported to
be 7.7% in a large US survey, in which a total of 3.6% of
patients were completely incontinent following radical
prostatectomy [55]. Improvement in continence function
continues postoperatively over 12–24 months [56]. Surgi-
cal treatment for incontinence should therefore not be
undertaken for at least 1 year after radical prostatecto-
my.
Radical Perineal Prostatectomy
This approach is favored by some urologists because it
supposedly provides an access for radical prostatectomy
that reduces postoperative morbidity. A lower intraopera-
tive blood loss has been reported in comparison to retro-
pubic radical prostatectomy [57]. The argument against
the perineal approach is that tumor control is less likely to
be achieved in all cases. However, there are no random-
ized studies substantiating this view, and tumor control
rates which are the same as after retropubic radical pros-
tatectomy have been reported [58]. However, for lym-
phadenectomy a second procedure is required, and some
of the potential advantages of the perineal approach are
foregone.
Laparoscopic Radical Retropubic Prostatectomy
This is a new technique which has recently been intro-
duced. It offers good exposure and reduced peri- and post-
operative morbidity while allowing the performance of a
pelvic lymphadenectomy at the same time. While this
technique promises positive new developments, it is too
early to make definite judgements at present.
Nerve-Sparing Technique
Nerve-sparing radical prostatectomy can be routinely
done in all younger patients and those who express con-
cern about postoperative impotence. However, in many
cases of T2b or most of T3 disease this may not be possi-
ble without compromising the goal of complete tumor
excision. While postoperative potency will generally de-
pend on the patient’s age and preoperative sexual func-
tion, it can be preserved for some patients if the neurovas-
cular bundle on the side contralateral to the tumor in T2a
disease is spared [59]. Contraindications are capsular pen-
etration and tumor close to the apex [60]. The preserva-
tion of potency is achieved in 41% if one and in 63% if
both neurovascular bundles are preserved [61].
Conclusions
While especially the issue of the role of percutaneous
radiotherapy and interstitial brachytherapy has not been
clearly defined from a surgical point of view, it is clear
that radical prostatectomy is a curative treatment with
excellent survival rates for organ-confined prostate can-
cer. Thus, patients with a life expectancy of at least 10
years and T1 or T2 disease should be treated by radical
prostatectomy. Patients with pT3 disease will be included
in the group of cT2 patients due to errors of staging. For
these, adjuvant treatment strategies need to be investi-
gated systematically.
In contrast to surgery, radiotherapy does have the defi-
nite potential to cure locally advanced prostate cancer. In
localized prostate cancer, however, it must be considered
an alternative treatment option as long as definite long-
term outcome data are missing, and should certainly be
offered to all patients who are not candidates for radical
prostatectomy.
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